implantation itself has been infection in the tumour, which was usually a sequel of overt cerebrospinal fluid rhinorrhcea. Such a local infection can readily spread to give meningitis. Among the last 30 implants giving 50,000 rads (January 1968 to March 1969 there has been no instance of local infection, after the introduction of two important measures:
(1) Adequate pre-implant antiseptic treatment with chlorhexidine (Hibitane) (1/1,000) nasal spray, combined with antibiotic cover with cloxacillin for five days after implant.
(2) Starting trimethoprim (250 mg) and sulphamethoxazole (500 mg) twice daily immediately a cerebrospinal fluid leak is reported, and continuing this until the leak either heals spontaneously or is repaired.
Loss of anterior pituitary function to the extent that cortisone or thyroxine became necessary occurred after 28 % of implants (Table 2) or in 20% if we exclude those deliberately given total ablation doses. Loss of ACTH or TSH was not necessarily combined with loss of GH secretion. Among 15 patients attaining normal GH levels, 11 also lost other anterior pituitary function; among the 18 hypopituitary patients needing thyroxine and cortisone, there were 7 who still had abnormally high-GH levels (Fig 3) .
Diabetes insipidus occurred after 16 implants (17%), but in only 4 has permanent vasopressin treatment been required. Hyponatremia due to 'inappropriate' ADH was observed after one of the implants.
Conclusions
(1) A satisfactory clinical response was achieved by yttrium implantation in more than half of 80 acromegalic patients. Hypopituitarism occurred in a quarter. Cerebrospinal fluid rhinorrhea occurred in 13 % and local infection in 12%.
(2) Considerable improvement in the visual field defects was observed in all 5 patients so affected.
(3) The changes observed in serum GH levels did not always mirror the clinical response; a satisfactory clinical response appeared to need both a pronounced percentage fall as well as a fall to below an absolute level between 10-50 ng/ml. Plasma Growth Hormone in the Long-term Follow Up of X-ray-treated and Untreated Acromegalics The growth hormone (HGH) levels of 42 untreated acromegalic patients were measured by the radioimmunoassay of Hunter & Greenwood (1964) . The test procedure consisted of 6-8 samples taken at half-hourly intervals with oral glucose, 50 g, being given immediately after the third sample. Tests conducted on different occasions within a period of six months on the same patients gave mean HGH values which were within or just outside the overlap of their SEMs.I The range for untreated acromegalics was 5-500 ng HGH/ml plasma, values being expressed in terms of MRC HGH Standard A. Ten patients were reassessed by HGH assay before and at intervals after X-ray therapy (3,500 rads). HGH levels did not change during the first 6 months after this treatment. During the next 18 months HGH levels either remained unchanged (3 cases), fell (5 cases) or increased (2 cases Thirteen patients were treated surgically, 6 by transfrontal (Professor Valentine Logue) and 7 by transsphenoidal (Mr R A Williams) hypophysectomy. Two patients with marked changes of acromegaly had clinically inactive disease. In one this was attributed to previous external radiotherapy (6,000 r) but the other apparently represented the condition of 'burnt out' acromegaly.
The basal plasma GH levels of individual patients were found to vary widely from day to day and in 6 patients who had 2+-hour saline infusions there were marked fluctuations about the mean level. The mean fasting plasma GH levels were related to the degree of physical disfigurement. In severe cases the levels exceeded 100 ng/ml, in mild cases they were in the range 10-30 ng/ml. The patient with 'burnt out' acromegaly had a mean fasting GH level of 3 5 ng/ml. After operation the spontaneous fluctuations in the fasting levels of GH persisted but the mean levels had fallen by 40% or more in 11 patients and in 5 of these to 5 ng/ml or less. GH levels in one patient, which rose after partial removal of an invasive tumour, subsequently fell after X-ray therapy (4,000 r).
All patients had intravenous glucose (25 g) and 6 had oral glucose (50 g) tests at the time of diagnosis. A partial reduction of GH levels was observed in 4 patients but in all the area under the GH curve (Sonksen et al. 1967) was above the range found in 12 normal subjects. A rise of GH levels after glucose was observed in 3 patients, in one to oral, but not to intravenous glucose before and after surgery in spite of a tenfold reduction in basal GH levels.
Intravenous glucose tests were repeated in all patients after operation and in only one was the GH level suppressed. The area under the GH curve after intravenous glucose was reduced appreciably by operation in 12 patients but in only 4 to within the range found in normal subjects.
Intravenous insulin tests (0-3-0-6 units/kg body weight) were performed on 11 patients pre-operatively and 7 responded with a rise in GH levels. Six of the 11 patients (including 3 'non-responders') were retested after operation and all had a significant elevation of GH levels in response to hypoglycemia. In one patient the highest levels of GH recorded were during the post-operative insulin test.
Two untreated patients had GH measurements during intravenous glucose tests at intervals over a three-year period. The area under the GH curve increased during the period of observation. Eight patients treated surgically were followed for periods of up to four years. In 6 the area under the GH curve in the first post-operative intravenous glucose test (one to three months after operation) was similar to the value obtained at the end of the period of follow up. One patient referred to previously responded to X-ray therapy; in the other, despite an increase in GH levels there had been no clinical evidence of progress of the disease.
Measurements of plasma GH levels have shown disordered regulation of GH secretion as well as raised fasting levels in acromegaly. After surgical treatment the fasting plasma GH levels usually fell but seldom to the normal range. In some patients the disordered regulation of secretion was partly corrected. Cryogenic surgery, the destruction of tissues by intense cold, was introduced into medicine by Cooper in 1963 and has since found application in many fields. It produces death of cells by a combination of effects, among which rupture of membranes, crystallization and ischimia are probably important. One of its uses has been in the treatment of functioning pituitary tumours and ablation of the normal pituitary gland. The technique uses liquid nitrogen at temperatures as low as -196°C, which is delivered to the pituitary gland via a cannula inserted under stereotaxic control through drill holes into the pituitary fossa (Rand et a. 1964). The duration of freezing and the number of lesions made depend on the size of the gland, and it should be possible to predict accurately the size of the lesion produced if the 'Dr Harrison died in June 1969 
